8K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): August 14,
2018
INNOVUS
PHARMACEUTICALS, INC.
(Exact name of
registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State or other
jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS Employer
Identification No.)
|
|
8845 Rehco Road, San Diego, CA
|
|
92122
|
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 249-7873
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
In this report,
“Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 2.02 – Results of Operations and Financial
Condition
On
August 14, 2018, the Company issued a press release reporting our
financial results for the second quarter ended June 30, 2018. The
full text of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
Item
9.01 -- Financial Statements and Exhibits
(d)
Exhibits
|
Exhibit No.
|
Description
|
|
|
Press
release issued
August 14, 2018, reporting financial results for the second quarter
ended June 30, 2018
|
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date: August 14, 2018
|
By:
|
/s/ Randy Berholtz
|
|
|
|
|
Randy
Berholtz
Executive Vice
President, Corporate Development
and General
Counsel
|
EXHIBIT
INDEX
|
Exhibit No.
|
Description
|
|
|
Press
release issued
August 14, 2018, reporting financial results for the second quarter
ended June 30, 2018
|
|
|
|